Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

This Cochrane review found no clear superiority among treatments for central serous chorioretinopathy, with low-dose photodynamic therapy, supplements, and eplerenone showing slightly higher probabilities of improving visual acuity, but evidence remains uncertain due to biases and small study sizes.

In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.

Clascoterone safely promotes hair growth similar to minoxidil.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This study found that dutasteride was more effective than finasteride in increasing total and thick hair count and reducing thin hair count in men with AGA, with both drugs having similar side effect profiles.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

In this double-blind study, a novel hyaluronic acid gel for lip augmentation was found to be as effective and safe as a commercially available gel, with similar adverse event profiles and high patient and investigator improvement ratings over six months.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

The research concluded that in men with androgenetic alopecia, dutasteride was more effective than finasteride at increasing hair count after 24 weeks, with similar side effect profiles.

This review examines the growing global demand for diverse tea products, highlighting their health benefits and the economic challenges tea-producing countries face, while also exploring the rise of tea-based nutraceuticals, confectionery, toiletries, and cosmeceuticals.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

This review discusses the diversification of tea products and their associated health benefits, highlighting the economic challenges faced by tea-producing countries and the global marketing strategies of the tea industry, but reports no new experimental findings.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

Dutasteride is more effective than finasteride for hair growth with similar side effects.

Lichen planus may be associated with a higher risk of metabolic syndrome.

Dutasteride works better than finasteride for hair growth with similar side effects.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This review highlights that iPSC-derived artificial platelets offer a promising alternative to platelet-rich plasma for regenerative medicine, with standardized manufacturing and reproducible pharmacological properties, addressing variability issues associated with donor-derived platelets and showing therapeutic potential in preclinical models of osteoarthritis.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that PRP injections may safely improve penile curvature and PDQ scores in men with stable-phase Peyronie's Disease, although the curvature reduction observed was not enough to determine long-term clinical significance.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study found that patients with rheumatoid arthritis who discontinued and restarted methotrexate had less improvement in disease activity, more side effects, and more initial comorbidities than those who persisted on the therapy.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.